No­var­tis re­turns to ap­pel­late court, re­quest­ing re­hear­ing and re­ver­sal in Gilenya patent case

No­var­tis may have suf­fered a set­back in court over its block­buster neu­ro­science drug Gilenya, but the phar­ma gi­ant isn’t done fight­ing for it.

A month af­ter the US Court of Ap­peals for the Fed­er­al Cir­cuit ruled 2-1 against No­var­tis in a patent in­fringe­ment case, the Swiss phar­ma gi­ant filed a mo­tion re­quest­ing to be heard ei­ther by a new pan­el or en banc, which means all judges of the court hear the case, in­stead of 1 or a pan­el of 3. By law, there are 12 judges on the court.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.